<DOC>
	<DOCNO>NCT00995709</DOCNO>
	<brief_summary>The purpose pivotal trial evaluate subcutaneous ( SQ ) AIN457 adjunctive therapy reduce rate exacerbation posterior uveitis panuveitis secondary Behçet 's disease 24 week study therapy compare standard care alone .</brief_summary>
	<brief_title>Phase III Study Refractory Behcet 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Behcet Syndrome</mesh_term>
	<criteria>Patients Behçet 's disease history recurrent uveitis least one eye . Documented evidence &gt; 2 recurrent exacerbation either intermediate uveitis , posterior uveitis panuveitis study eye within past 6 month ( could include current exacerbation patient acute exacerbation screen ) . Exacerbations fulfil study inclusion criterion must one follow record patient patient medical record recurrent exacerbation : &gt; 2+ vitreous haze &lt; 2+ anterior chamber cell grade ( intermediate posterior uveitis ) &gt; 2+ vitreous haze &gt; 2+ anterior chamber cell grade ( panuveitis ) presence retinal infiltrates vasculitis hemorrhage document &gt; 10 ETDRS letter 2 line Snellen decrease visual acuity attribute ocular inflammation secondary recurrent exacerbation Behçet 's disease . Requirement either follow immunosuppressive therapy least 3 past 6 month treatment prevent exacerbation ocular inflammation relate Behçet 's disease : Prednisone equivalent &gt; 10 mg daily The need least &gt; 1 periocular injection &gt; 1 intravitreal corticosteroid injection study eye within past 6 month ( last injection must give within 6 week screen ) Treatment cyclosporine , tacrolimus , azathioprine , mycophenolate mofetil , mycophenolic acid methotrexate either monotherapy combination without steroid . ( Patients treat time chlorambucil cyclophosphamide eligible study . ) Patients meet specify criterion immunomodulatory therapy eligible enrollment intolerant systemic immunomodulatory therapy determine study investigator . Subjects infectious uveitis , uveitis due cause Behçet 's disease , uveitis unknown etiology . Less severe ( i.e . anterior ) uveitis associate Behçet 's disease . Ocular treatment Treatment intravitreal antiVEGF agent administer study eye within 3 month prior study screen . Treatment inject implantable corticosteroid release device ( i.e. , flucinolone acetonide implant , Retisert® ) study eye within last 3 year . Intraocular surgery laser photocoagulation study eye within last 6 week prior screen except diagnostic vitreous aqueous tap smallgauge needle . Systemic condition treatment Treatment live liveattenuated vaccine ( include vaccine varicellazoster virus measles ) within 2 month prior screen . Any systemic biologic therapy ( e.g . interferon , infliximab , daclizumab , etanercept , adalimumab ) give intravenously subcutaneously within 3 month prior screen prior treatment AIN457 . Any prior treatment systemic alkylating agent ( cyclophosphamide , chlorambucil ) . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Behçet 's disease ,</keyword>
	<keyword>intermediate uveitis</keyword>
	<keyword>panuveitis</keyword>
	<keyword>posterior uveitis</keyword>
	<keyword>uveitis</keyword>
</DOC>